Is your Active Pharmaceutical Ingredient quality control strategy up to standard?

Author
Published on

The last couple of years we see a trend of health authorities (HAs) across the globe increasingly raising questions on the control strategy of active pharmaceutical ingredients (APIs) when reviewing Drug Master files (DMFs, including CEP DMFs) or drug substance sections (3.2.S). Based on ICH Q11 and related guidance, HAs are expecting more information on how API manufacturers control and maintain the quality of their APIs, from development throughout the lifecycle. In this whitepaper, we will explain more about control strategies for APIs. 

Explore Starodub updates

Major Changes Ahead for CTD Modules 2 & 3: ICH Releases Draft M4Q(R2) for Public Consultation

Nonclinical safety assessment with New Approach Methodologies (NAMs): partner with us for regulatory success! 

Our 2025 company outing was unforgettable

Valentyna Starodub
Founder and Chief Executive Officer
Valentyna Starodub

Let's Connect

Talk to an expert